Accuracy of low-cost point-of-care FebriDx test for diagnosing COVID-19

  • Clark TW & al.
  • J Infect
  • 21 Jun 2020

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Researchers at the University of Southampton have reported that a low cost, instrument-free, disposable point-of-care test (POCT) can accurately diagnosis COVID-19.

FebriDx (Lumos diagnostics, Sarasota, Florida, US) is a CE-marked POCT that detects two host response proteins, Myxovirus resistance protein A and C reactive protein, in finger-prick blood samples, and is designed to distinguish viral from bacterial respiratory infection.

This real-world study examined the diagnostic accuracy of FebriDx in hospitalised patients during the first wave of the pandemic. FebriDx results were compared to the reference standard of SARS-CoV-2 polymerase chain reaction (PCR) on combined nose and throat swabs.

FebriDx was performed on 251 patients and gave a valid result in 248. A total of 118 of 248 (48%) were PCR positive for COVID-19.

FebriDx results were available after 10 minutes compared with 1.7 (95% CI, 1.6-2.1) hours with POCT using PCR and 23.4 (95% CI, 17.2-31.1) hours with laboratory PCR testing.

Sensitivity of FebriDx for the identification of COVID-19 was 93 per cent (95% CI, 87%-97%) and specificity was 86 per cent (95% CI, 79%-92%). Positive and negative likelihood ratios were 6.73 (95% CI, 4.37-10.37) and 0.08 (95% CI, 0.04-0.15), respectively.

In the multivariate model, age, sex and other clinical features did not contribute significantly to the effect of the FebriDx result in distinguishing patients with and without COVID-19.

Presenting the result in the Journal of Infection, the authors suggest FebriDx could be deployed in the NHS as a front door triage tool.